Patents Assigned to SmithKline Beecham Biologicals (s.a.)
-
Publication number: 20090191234Abstract: This invention relates to three newly-identified, distinct groups of antigenic peptides [LB1(f) peptides] from the same region of the P5-like fimbrin protein discovered using sequence data from the fimbrin protein of many Haemophilus influenzae strains. The invention additionally provides chimeric polypeptides that carry one or more representatives of such peptides from different groups and which induce an immunogenic response in animals to Haemophilus influenzae. The peptides and polypeptides of the invention will be useful in vaccine compositions which provide protection against a wide range of H. influenzae strains.Type: ApplicationFiled: December 23, 2008Publication date: July 30, 2009Applicants: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION, SMITHKLINE BEECHAM BIOLOGICALS S.A.Inventors: Lauren Bakaletz, Joseph Cohen, Guy Dequesne, Yves Lobet
-
Patent number: 7432366Abstract: Provided are Moraxella catarrhalis BASB034 polypeptides and immunogenic fragments of BASB034 polypeptides. Preferably, the immunogenic fragments have at least 15 amino acids that match an aligned contiguous segment of SEQ ID NOs:2, 4, 6 or 8. The immunogenic fragments, when administered to a subject in a suitable composition (which can include an adjuvant, or a suitable carrier coupled to the fragment) raise an immune response that recognizes a polypeptide having the sequence of SEQ ID NOs:2, 4, 6 or 8. The invention further provides immunogenic compositions containing BASB034 polypeptides and immunogenic fragments thereof, and a pharmaceutically acceptable carrier. Also provided are fusion proteins that contain BASB034 polypeptides and immunogenic fragments thereof.Type: GrantFiled: March 10, 2003Date of Patent: October 7, 2008Assignee: SmithKline Beecham Biologicals S.A.Inventor: Jean-Louis Ruelle
-
Publication number: 20080226672Abstract: An adjuvant composition comprising monophosphoryl lipid A or a derivative of monophposphoryl lipid A adsorbed onto an aluminium salt particle.Type: ApplicationFiled: February 28, 2008Publication date: September 18, 2008Applicant: SMITHKLINE BEECHAM BIOLOGICALS, S.A.Inventor: Nathalie Garcon
-
Publication number: 20080213295Abstract: The present invention is generally directed to HER-2/neu fusion proteins, nucleic acid molecules encoding HER-2/neu fusion proteins, viral vectors expressing HER-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the HER-2/neu fusion proteins and/or nucleic acid molecules encoding the HER-2/neu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the HER-2/neu protein, including for uses in the treatment of malignancies associated with the HER-2/neu oncogene.Type: ApplicationFiled: April 9, 2008Publication date: September 4, 2008Applicants: CORIXA CORPORATION, SMITHKLINE BEECHAM BIOLOGICALS S.A.Inventors: Martin A. Cheever, Dirk Gheysen
-
Patent number: 7375091Abstract: The present invention is generally directed to HER-2/neu fusion proteins, nucleic acid molecules encoding HER-2/neu fusion proteins, viral vectors expressing HER-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the HER-2/neu fusion proteins and/or nucleic acid molecules encoding the HER-2/neu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the HER-2/neu protein, including for uses in the treatment of malignancies associated with the HER-2/neu oncogene.Type: GrantFiled: May 9, 2001Date of Patent: May 20, 2008Assignees: Corixa Corporation, SmithKline Beecham Biologicals s.a.Inventors: Martin A. Cheever, Dirk Gheysen
-
Patent number: 7371390Abstract: Novel combined vaccine compositions are provided, comprising a hepatitis B viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a herpes simplex viral antigen, a VZV antigen, a Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.Type: GrantFiled: November 8, 2004Date of Patent: May 13, 2008Assignee: SmithKline Beecham Biologicals s.a.Inventor: Martine Anne Cecile Wettendorff
-
Patent number: 7348009Abstract: The present invention provides a novel treatment for allergy comprising a recombinant allergen with reduced enzymatic activity, thereby reducing the potential for an allergic response upon contact with a wild-type allergen.Type: GrantFiled: November 16, 1998Date of Patent: March 25, 2008Assignee: SmithKline Beecham Biologicals, s.a.Inventors: Claudine Bruck, Alex Bollen, Paul Jacobs, Marc Georges Francis Massaer
-
Patent number: 7285280Abstract: The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.Type: GrantFiled: August 15, 2000Date of Patent: October 23, 2007Assignee: SmithKline Beecham Biologicals s.a.Inventors: Brigitte Desiree Alberte Colau, Francoise Denamur, Isabelle Knott, Annick Poliszczak, Vincent Vande Velde
-
Publication number: 20070243580Abstract: The invention provides BASB019 polypeptides and polynucleotides encoding BASB019 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: ApplicationFiled: March 5, 2004Publication date: October 18, 2007Applicant: SmithKline Beecham Biologicals S.A.Inventor: Jean-Louis Ruelle
-
Patent number: 7238349Abstract: The invention provides a monovalent influenza vaccine comprising a low dose of egg-derived influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak or has the potential to be associated with a pandemic outbreak, in combination with an aluminium adjuvant. The invention also provides vaccine kits comprising a combination of a parenteral and a mucosal influenza vaccine, wherein the combined dose of antigen is no more than the conventional antigen dose. Also provided are methods for preparing the vaccines.Type: GrantFiled: September 27, 2000Date of Patent: July 3, 2007Assignees: SmithKline Beecham Biologicals, s.a., Saechsisches Serumwerk DresdenInventors: Erik D'Hondt, Norbert Hehme
-
Patent number: 7220551Abstract: Novel combined vaccine compositions are provided, comprising a herpes simplex virus (HSV) antigen and a HPV antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a hepatitis B viral antigen, a VZV antigen, a HCMV antigen, Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.Type: GrantFiled: June 29, 2006Date of Patent: May 22, 2007Assignee: SmithKline Beecham Biologicals S.A.Inventor: Moncef Mohamed Slaoui
-
Patent number: 7198920Abstract: The present invention is generally directed to HER-2/neu fusion proteins, nucleic acid molecules encoding HER-2/neu fusion proteins, viral vectors expressing HER-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the HER-2/neu fusion proteins and/or nucleic acid molecules encoding the HER-2/neu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the HER-2/neu protein, including for uses in the treatment of malignancies associated with the HER-2/neu oncogene.Type: GrantFiled: January 28, 2000Date of Patent: April 3, 2007Assignees: Corika Corporation, SmithKline Beecham Biologicals, S.A.Inventors: Martin A. Cheever, Dirk Gheysen
-
Patent number: 7192065Abstract: A system for making a connection between the interior and exterior of a compartment, comprising a door opening through the compartment wall, a connector body which can engage with the wall, and having a connection port through it, and a removable cover on the connector body. The body is engaged with the door opening, and an inner door within the compartment engages and removes the cover. A preferred construction creates a single line of confidence seal. The system is particularly suited for sterile compartments.Type: GrantFiled: August 13, 2001Date of Patent: March 20, 2007Assignee: SmithKline Beecham Biologicals s.a.Inventors: Jacques Thilly, Christian Vandecasserie
-
Patent number: 7169391Abstract: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses.Type: GrantFiled: August 10, 2005Date of Patent: January 30, 2007Assignee: Smithkline Beecham Biologicals (S.A.)Inventors: Patricia Marie Momin, Nathalie Marie-Josephe Garcon
-
Patent number: 7147862Abstract: The present invention provides vaccine compositions comprising 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccines compositions are potent inducers of CTL and ? IFN responses.Type: GrantFiled: August 12, 1997Date of Patent: December 12, 2006Assignee: SmithKline Beecham Biologicals (S.A.)Inventors: Jean-Paul Prieels, Nathalie Marie-Josephe Claude Garcon-Johnson, Moncef Slaoui, Pietro Pala
-
Patent number: 7144703Abstract: Novel vaccine compositions are provided comprising a hepatitis B antigen formulated with aluminium phosphate. The vaccine compositions may additionally contain an inactivated hepatitis A virus, aluminium hydroxide and formol. The combined hepatitis A and B vaccine formulations can, if desired, be administered to human subjects in a 2 dose regimen. Suitable formulations are illustrated.Type: GrantFiled: July 1, 2004Date of Patent: December 5, 2006Assignee: SmithKline Beecham Biologicals, s.a.Inventors: Claude Artois, Michael J Clark, Stefan Gabriel Jozef Thoelen, Clothilde Thiriart
-
Patent number: 7122197Abstract: The invention provides BASB020 polypeptides and polynucleotides encoding BASB020 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: May 7, 1999Date of Patent: October 17, 2006Assignee: SmithKline Beecham Biologicals S.A.Inventor: Joelle Thonnard
-
Patent number: 7112331Abstract: The present invention relates to compositions for the treatment or prevention of Zoster of individuals infected with Varicella Zoster virus (VZV), and to the prevention and treatment of Varicella infections. The compositions of the invention comprise the protein encoded by VZV gene 63 or an immunologically active derivative thereof. The invention further relates to compositions containing DNA or RNA corresponding to VZV gene 63.Type: GrantFiled: February 4, 1997Date of Patent: September 26, 2006Assignees: SmithKline Beecham Biologicals, s.a., University of LiegeInventors: Bernard Rentier, Catherine Sadzot
-
Patent number: 7101560Abstract: Novel combined vaccine compositions are provided, comprising a herpes simplex virus (HSV) antigen and a HPV antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a hepatitis B viral antigen, a VZV antigen, a HCMV antigen, a Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.Type: GrantFiled: December 12, 2003Date of Patent: September 5, 2006Assignee: SmithKline Beecham Biologicals s.a.Inventor: Martine Anne Cecile Wettendorff
-
Publication number: 20060147462Abstract: This invention provides BASB020 polypeptides and polynucleotides encoding BASB020 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: ApplicationFiled: February 28, 2006Publication date: July 6, 2006Applicant: SmithKline Beecham Biologicals S.A.Inventor: Joelle Thonnard